Exyte increases order intake, sales, and profitability

  • Drive usage up more than 25% year over year, mark a new milestone 9M-high with €6.5 billion

  • Total sales grew by almost 60% to €5.3 billion

  • Strong sales growth in all three business segments

  • Adjusted EBIT increased by 73% to €308 million; adjusted EBITDA increased by 70% to € 340 million

  • Acquisition of Airgard Inc., enhances product portfolio of Technology and Services business

  • New employee branding to attract new talent

STUTTGART, Germany, Nov. 9, 2022 /PRNewswire/ — Exyte GmbH (Exyte), a world leader in the design, engineering, and delivery of technology buildings, continued its strong performance in the first nine months of the fiscal year 2022 progressing successfully. up his accelerated path of growth, his ‘Ten Path’.



In the first nine months of 2022, Exyte recorded an increase of almost 60% year-on-year in sales. The stock was sold at an all-time-high €5.3 billion (9M/2021: € 3.4 billion) thanks to major projects in all business areas especially in the APAC and EMEA regions. Both regions contributed strongly to the consumption of orders. From January to September it reached €6.5 billion (9M/2021: €5.1 billion), an increase of more than 25% compared to the previous year.

With an adjusted EBITDA of € 340 million (9M/2021: €200 million) and adjusted EBIT of €308 million (9M/2021: €178 million) Exyte improves its revenue. EBITDA margin was estimated at 6.4% (9M/2021: 5.9%), the adjusted EBIT margin reached 5.8% (9M/2021: 5.3%), both improved by 0.5% points year over year.

“Our well-developed business management system reflects our strong management position. The businesses we serve continue to invest unaltered. This shows despite short-term economic shocks,” he said. said Dr. Wolfgang Büchele, CEO of Exyte.

Good outlook despite current economic conditions

“Exyte is successful in its ‘Road to Ten’. Our estimated revenue of €7 billion by 2022 brings us closer to our goal of reaching €10 billion in sales in 2027. With successful projects and an order of 8.2 billion, We are well positioned for successful progress. “However, we monitor developments and their specific effects in our business and make problems if necessary.”

Also Read :  Meta, Microsoft Vacate Offices In US Over WFH, Massive Layoffs: Report

Exyte has confirmed the positive outlook at the end of the year. According to the increase in sales, it is expected to increase the adjusted EBITDA and the adjusted EBIT. For 2022 the company sees an adjusted EBITDA of around €450 million, compared to an adjusted EBIT of over €400 million.

Growth in all business sectors, Biopharma & Life Sciences and Data Centers with customer development

In the first nine months of 2022, all three business groups received major new projects in all regions. With a sales volume of approximately 87% of the group’s total sales, the business segment High Tech Building recorded an increase in sales of approximately 55% to € 4.6 billion (9M/2021: €3.0 billion). Driven by the continued development of the semiconductor industry, incoming orders increased by almost a quarter to € 5.5 billion (9M/2021: €4.5 billion). Cell manufacturers also benefit from Exyte’s clean and dry room expertise. Exyte sees more sales opportunities in this business in the coming years, as so-called gigafabs are planned around the world for the production of battery cells and batteries. a.

Biopharma & Life Sciences sales almost doubled in the first nine months. The group’s sales reached €477 million (9M/2021: €247 million) due to major internal projects Singapore and Malaysia. Biopharma & Life Sciences accounts for 9.0% of the group’s total sales (9M/2021: 7.3%). The order reached €477 million (9M/2021: €384 million). Inside Dutch, Exyte is building a specialized mRNA center in Halle. Biopharma projects are currently underway for global pharmaceutical companies. Exyte recently opened a new in-house Life Sciences Office Cork, Ireland. The Irish medicine sector has grown rapidly in recent years. Exyte expects significant internal investments Ireland in projects ranging from biotechnology to packaging, Active Pharmaceutical Ingredients and cell and gene therapy.

Also Read :  9 ways the circular economy can help avert the climate crisis

Sales of the Data Center segment increased by 74% to reach € 181 million (9M/2021: €104 million). The order intake increased by more than 130% to € 409 million (9M/2021: €175 million). The business unit currently performs the main data functions internally Austria, Denmark, Dutch, Israel, Malaysiaand Taiwanetc.

Plan the growth of the Technology and Services division

Exyte recently completed the acquisition of Airgard Inc., a US specialist in gas filtration technology. Major players in the semiconductor industry are using Airgard’s liquid filter. The acquisition of Airgard strengthens Exyte’s position to support its customers with specialized solutions for their gas applications, as well as the growing expertise derived from Environmental, Social and Governance (ESG) ) rules and requirements.

This next acquisition builds on Exyte’s strategy of vertical integration by strengthening its business in the competitive technology sector’ and our services. In 2021, Exyte acquired the Critical Process Systems Group and became part of the Technology & Services (T&S) Business Area. T&S has organizations that provide cleanroom technology, installation services, and specialized equipment for its customers’ subsystems as well as outsourced manufacturing. (OSM). In the first nine months of 2022 Technology & Services almost doubled sales to € 555 million (9M/ 2021: € 280 million) contributing 10% to the group’s total sales (9M/2021: 8.0%). Incoming orders more than doubled to €788 million (9M/2021: €336 million).

Also Read :  CEE MARKETS-Hungary's Richter falls on windfall tax on drug producers

Advance the ‘Way to Ten’ – New Employer Branding

Targeted marketing is a cornerstone of Exyte’s ‘Next Level’ future strategy. In this agenda the company has defined many areas of action to be successful in its ‘Ten Way’. Another area of ​​activity is to be the employer of choice for current and future employees. In this context, Exyte recently presented a new workplace platform that is the platform for talent acquisition and global investment. About 15,000 employees are expected to work for Exyte in 2027, more than double the number in 2021. September 2022 Exyte employs nearly 9,000 people worldwide.

Financial Indicators at a Glance




2022 vs. 2021

Intake Order

€6.5 billion

€5.1 billion



€5.3 billion

€3.4 billion


Adjusted EBITDA



+70.0 %

Adjusted EBITDA margin

6.4 %

5.9 %

+0.5 PP

Adjusted EBIT



+73.0 %

Adjusted EBIT margin

5.8 %

5.3 %

+0.5 PP

*The percentage is calculated based on prices per million.

For more information about the 9M-end 2022 please visit the website exyte.net.

About Exyte

Exyte is a global leader in the design, engineering, and delivery of clean and efficient environments for advanced industries. With expertise developed over more than a century, we serve clients in the specialty markets of semiconductors, batteries, pharmaceuticals, biotechnology, and data centers. data. Exyte offers a wide range of services from consulting to managing the implementation of turnkey solutions with the highest standards in security and efficiency to our customers worldwide. We create a better future by enabling core businesses to improve the quality of modern life. In 2021, Exyte achieved sales of EUR 4.9 billion with 7,400 employees worldwide.


René Ziegler
Vice President Corporate Communications & Investor Relations
+49 711 88044606
+49 172 5838786
[email protected]

Credit: https://mma.prnewswire.com/media/1487100/Exyte_Logo.jpg



See earlier:https://www.prnewswire.co.uk/news-releases/strong-business-performance-in-9m2022-exyte-increases-order-intake-sales-and-profitability-301672765.html


Leave a Reply

Your email address will not be published.

Related Articles

Back to top button